



For Immediate Release.....

NBMI Presents Business Program at BioVenture East Forum, Montreal

Edmond, OK (July 1, 2007): NanoBioMagnetics Inc. (NBMI) recently announced that the company had been invited to present its business program at the BioVenture Forum East Conference being held June 18 – 20, in Montreal, Canada. NBMI was one of several biotechnology and pharmaceutical ventures invited to present their respective programs to representatives of investment houses and pharmaceutical organizations, however, NBMI was the only nanobiomaterials company to present.

The conference, sponsored by the Biotechnology Industry Organization (BIO), in partnership with 14 state biotechnology associations and BIOTECanada, showcased selected companies to leading North American venture capital firms in the life sciences field.

Charles Seeney, NBMI's founder and President, and Dr. Jim Klostergaard, NBMI's Chief Science Adviser and Professor of Molecular and Cellular Oncology at the University of Texas M.D. Anderson Cancer Center, gave a joint presentation focusing on their Organ-Assisting- Device (OAD) technology platform for the tumor-specific delivery of chemotherapeutics.

In the presentation, Seeney initially focused on the broad implications of OAD technology platforms, and Klostergaard followed with a discussion of the results of tumor-specific magnetic vectoring research in ovarian and breast cancer models. The technology being developed is based on external, shaped magnetic fields, to target or vector magnetic nanoparticles, carrying a therapeutic, to a tumor site. Research results have been recently presented at national and international conferences and published in scientific journals.

Seeney points out that nanotechnology is an enabling technology, and, as such, requires collaborations for concept development and validation, "Our research team brings together the multiple scientific elements essential for assessing the value of our vectoring technology in delivering a therapeutic." The purpose for presenting at this conference, according to Seeney, was to further the process of bringing nanotechnology into the biomedical arena, which he refers to as *nanobioconvergence*. A term which Seeney says we will begin to hear more often.

What's next for NBMI? Seeney and Klostergaard are looking ahead to expanding the platform technology to other cancer models and developing a successful tumor-specific delivery technology that can be applied in a clinical setting. "Obviously," says Seeney, "funding is Key," which is what brought them to Montreal.

Contact: [Mr. Dennis Donaldson](#)

[Mr Charles Seeney](#)

Safe Harbor Statement: Certain statement included in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of products and services, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. The company's expectations regarding future revenues are dependent upon the ability to develop and supply products and services that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions are generally considered forward-looking statements. These statements reflect current expectations.